Table 6

Association of various non-DIPSS factors with outcome after adjustment for DIPSS

HSCT outcomeHR95% CIP
Overall mortality    
    Alternative donor* 1   
    HLA-matched related 0.65 0.40-1.06 .08 
    Other conditioning* 1   
    High-dose conditioning† 0.69 0.34-1.41 .31 
    HCT-CI   .13 
    PBSC* 1   
    Bone marrow 1.42 0.85-2.39 .18 
    JAK2 wild-type 1   
    JAK2-V617F mutant 0.76 0.36-1.57 .45 
    No splenectomy* 1   
    Splenectomy 0.51 0.26-1.00 .05 
Relapse or death    
    Alternative donor* 1   
    HLA-matched related 0.70 0.44-1.12 .13 
    Other conditioning* 1   
    High-dose conditioning† 0.73 0.36-1.49 .39 
    HCT-CI   .24 
    PBSC* 1   
    Bone marrow 1.47 0.89-2.45 .14 
    JAK2 wild-type 1   
    JAK2-V617F mutant 0.92 0.46-1.82 .80 
    No splenectomy* 1   
    Splenectomy 0.74 0.41-1.33 .32 
Relapse    
    Alternative donor* 1   
    HLA-matched related 0.73 0.28-1.86 .50 
    Other conditioning* 1   
    High-dose conditioning† 1.43 0.18-11.02 .73 
    HCT-CI   .46 
    PBSC* 1   
    Bone marrow 1.52 0.57-4.04 .40 
    JAK2 wild-type 1   
    JAK2-V617F mutant 2.16 0.54-8.65 .28 
    No splenectomy* 1   
    Splenectomy 1.24 0.46-3.31 .67 
NRM    
    Alternative donor* 1   
    HLA-matched related 0.69 0.40-1.18 .18 
    Other conditioning* 1   
    High-dose conditioning† 0.65 0.30-1.38 .26 
    HCT-CI   .08 
    PBSC* 1   
    Bone marrow 1.45 0.80-1.63 .23 
    JAK2 wild-type 1   
    JAK2-V617F mutant 0.67 0.29-1.52 .33 
    No splenectomy* 1   
    Splenectomy 0.57 0.27-1.22 .15 
HSCT outcomeHR95% CIP
Overall mortality    
    Alternative donor* 1   
    HLA-matched related 0.65 0.40-1.06 .08 
    Other conditioning* 1   
    High-dose conditioning† 0.69 0.34-1.41 .31 
    HCT-CI   .13 
    PBSC* 1   
    Bone marrow 1.42 0.85-2.39 .18 
    JAK2 wild-type 1   
    JAK2-V617F mutant 0.76 0.36-1.57 .45 
    No splenectomy* 1   
    Splenectomy 0.51 0.26-1.00 .05 
Relapse or death    
    Alternative donor* 1   
    HLA-matched related 0.70 0.44-1.12 .13 
    Other conditioning* 1   
    High-dose conditioning† 0.73 0.36-1.49 .39 
    HCT-CI   .24 
    PBSC* 1   
    Bone marrow 1.47 0.89-2.45 .14 
    JAK2 wild-type 1   
    JAK2-V617F mutant 0.92 0.46-1.82 .80 
    No splenectomy* 1   
    Splenectomy 0.74 0.41-1.33 .32 
Relapse    
    Alternative donor* 1   
    HLA-matched related 0.73 0.28-1.86 .50 
    Other conditioning* 1   
    High-dose conditioning† 1.43 0.18-11.02 .73 
    HCT-CI   .46 
    PBSC* 1   
    Bone marrow 1.52 0.57-4.04 .40 
    JAK2 wild-type 1   
    JAK2-V617F mutant 2.16 0.54-8.65 .28 
    No splenectomy* 1   
    Splenectomy 1.24 0.46-3.31 .67 
NRM    
    Alternative donor* 1   
    HLA-matched related 0.69 0.40-1.18 .18 
    Other conditioning* 1   
    High-dose conditioning† 0.65 0.30-1.38 .26 
    HCT-CI   .08 
    PBSC* 1   
    Bone marrow 1.45 0.80-1.63 .23 
    JAK2 wild-type 1   
    JAK2-V617F mutant 0.67 0.29-1.52 .33 
    No splenectomy* 1   
    Splenectomy 0.57 0.27-1.22 .15 
*

Referent category. HCT-CI was treated as a continuous variable.

†

Indicates BU, 16 mg/kg oral or intravenous equivalent; TBI, ≥ 12 Gy; treosulfan, 42 g/m2; and I-131–based conditioning.

View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal